These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36732902)

  • 21. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.
    Vinther-Jensen T; Larsen IU; Hjermind LE; Budtz-Jørgensen E; Nielsen TT; Nørremølle A; Nielsen JE; Vogel A
    Orphanet J Rare Dis; 2014 Jul; 9():114. PubMed ID: 25026978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication.
    Rusz J; Klempíř J; Tykalová T; Baborová E; Čmejla R; Růžička E; Roth J
    J Neural Transm (Vienna); 2014 Dec; 121(12):1529-39. PubMed ID: 24809686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease.
    Covey DP; Dantrassy HM; Zlebnik NE; Gildish I; Cheer JF
    J Neurosci; 2016 May; 36(18):4993-5002. PubMed ID: 27147652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Another Perspective on Huntington's Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD.
    Achenbach J; Saft C
    Brain Sci; 2021 Dec; 11(12):. PubMed ID: 34942923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive and social cognition deficits in Huntington's disease differ between the prodromal and the manifest stages of the condition: A scoping review of recent evidence.
    Cavallo M; Sergi A; Pagani M
    Br J Clin Psychol; 2022 Jun; 61(2):214-241. PubMed ID: 34651307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive decline in Huntington's disease expansion gene carriers.
    Baake V; Reijntjes RHAM; Dumas EM; Thompson JC; ; Roos RAC
    Cortex; 2017 Oct; 95():51-62. PubMed ID: 28843844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.
    Orth M; Gregory S; Scahill RI; Mayer IS; Minkova L; Klöppel S; Seunarine KK; Boyd L; Borowsky B; Reilmann R; Bernhard Landwehrmeyer G; Leavitt BR; Roos RA; Durr A; Rees G; Rothwell JC; Langbehn D; Tabrizi SJ;
    Hum Brain Mapp; 2016 Dec; 37(12):4615-4628. PubMed ID: 27477323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.
    Misiura MB; Lourens S; Calhoun VD; Long J; Bockholt J; Johnson H; Zhang Y; Paulsen JS; Turner JA; Liu J; Kara B; Fall E;
    J Int Neuropsychol Soc; 2017 Feb; 23(2):159-170. PubMed ID: 28205498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Language-Independent Acoustic Biomarkers for Quantifying Speech Impairment in Huntington's Disease.
    Fahed VS; Doheny EP; Collazo C; Krzysztofik J; Mann E; Morgan-Jones P; Mills L; Drew C; Rosser AE; Cousins R; Witkowski G; Cubo E; Busse M; Lowery MM
    Am J Speech Lang Pathol; 2024 May; 33(3):1390-1405. PubMed ID: 38530396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do I misconstrue? Sarcasm detection, emotion recognition, and theory of mind in Huntington disease.
    Larsen IU; Vinther-Jensen T; Gade A; Nielsen JE; Vogel A
    Neuropsychology; 2016 Feb; 30(2):181-9. PubMed ID: 26301773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease.
    Corey-Bloom J; Gluhm S; Herndon A; Haque AS; Park S; Gilbert PE
    J Huntingtons Dis; 2016; 5(1):91-6. PubMed ID: 27003664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners.
    Read J; Jones R; Owen G; Leavitt BR; Coleman A; Roos RA; Dumas EM; Durr A; Justo D; Say M; Stout JC; Tabrizi SJ; Craufurd D;
    J Huntingtons Dis; 2013; 2(2):159-75. PubMed ID: 25063513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
    Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
    Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
    Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EEG Functional Connectivity and Cognitive Variables in Premanifest and Manifest Huntington's Disease: EEG Low-Resolution Brain Electromagnetic Tomography (LORETA) Study.
    Delussi M; Nazzaro V; Ricci K; de Tommaso M
    Front Physiol; 2020; 11():612325. PubMed ID: 33391027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.